NH SPAC 2 Asset Resilience Ratio

Latest as of December 2025: 6.45%

NH SPAC 2 asset resilience ratio. NH SPAC 2 (206640) has an Asset Resilience Ratio of 6.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NH SPAC 2 (206640) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩18.17 Billion
≈ $12.31 Million USD Cash + Short-term Investments

Total Assets

₩281.63 Billion
≈ $190.86 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of NH SPAC 2 (2015–2025)

Asset resilience ratio of NH SPAC 2 from 2015 to 2025. This chart shows how NH SPAC 2's Asset Resilience Ratio has changed over time. Read NH SPAC 2 balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down NH SPAC 2's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NH SPAC 2 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩18.17 Billion 6.45%
Total Liquid Assets ₩18.17 Billion 6.45%

Asset Resilience Insights

  • Limited Liquidity: NH SPAC 2 maintains only 6.45% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

NH SPAC 2 Industry Peers by Asset Resilience Ratio

Compare NH SPAC 2's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
BMC Medical Co. Ltd. A
SHE:301367
Medical Devices 44.96%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Hironic Co. Ltd
KQ:149980
Medical Devices 17.42%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Adherium Ltd
AU:ADR
Medical Devices 15.45%

NH SPAC 2 Asset Resilience Ratio by Year (2015–2025)

NH SPAC 2 asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for NH SPAC 2.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 6.45% ₩18.17 Billion
≈ $12.31 Million
₩281.63 Billion
≈ $190.86 Million
-17.78pp
2024-12-31 24.23% ₩61.71 Billion
≈ $41.82 Million
₩254.67 Billion
≈ $172.59 Million
-9.20pp
2023-12-31 33.43% ₩76.20 Billion
≈ $51.64 Million
₩227.90 Billion
≈ $154.45 Million
+2.54pp
2022-12-31 30.89% ₩60.44 Billion
≈ $40.96 Million
₩195.66 Billion
≈ $132.59 Million
-4.72pp
2021-12-31 35.61% ₩68.45 Billion
≈ $46.39 Million
₩192.24 Billion
≈ $130.28 Million
-0.08pp
2020-12-31 35.68% ₩58.34 Billion
≈ $39.53 Million
₩163.47 Billion
≈ $110.78 Million
+14.27pp
2019-12-31 21.42% ₩21.69 Billion
≈ $14.70 Million
₩101.26 Billion
≈ $68.62 Million
-3.51pp
2018-12-31 24.93% ₩25.79 Billion
≈ $17.47 Million
₩103.44 Billion
≈ $70.10 Million
+1.63pp
2017-12-31 23.30% ₩25.20 Billion
≈ $17.08 Million
₩108.17 Billion
≈ $73.30 Million
+8.25pp
2016-12-31 15.05% ₩13.67 Billion
≈ $9.26 Million
₩90.79 Billion
≈ $61.53 Million
+5.49pp
2015-12-31 9.56% ₩6.86 Billion
≈ $4.65 Million
₩71.71 Billion
≈ $48.59 Million
--
pp = percentage points

About NH SPAC 2

KQ:206640 Korea Medical Devices
Market Cap
$121.47 Million
₩179.25 Billion KRW
Market Cap Rank
#18264 Global
#802 in Korea
Share Price
₩8360.00
Change (1 day)
-1.76%
52-Week Range
₩8360.00 - ₩13970.00
All Time High
₩36222.75
About

Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more